	Approved for u	S¢ un	ough 10/31/2002.	OMP 0031-003
LIS	Patent and Trademark Office:	II C	DEPARTMENT	OF COMMERCE

Substitute for form 1449A/PTO		Complete if Known	E	1
INFORMATION DISCLOSURE F	Application Number	09/939,816	SE	ا ا ا
STATEMENT BY APPLICANT - 3	Filing Date	August 27, 2001	Z	
JUN 1 1 2002	First Named Inventor	E. Farber	<u> </u>	C.2
(use as many sheets as necessary)	Art Unit	1614		2
	Examiner Name	Not yet assigned	8	8
Sheet 1 of 4 PADEMAN	Attorney Docket Number	14358-314	252	, _

			U.S. PATENT	DOCUMENTS
Examiner	Cite	Document Number	Publication Date	Name of Patentee or
Initials*	No. 1	Number -Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document
7	1	US-3,830,824	08/20/74	Margraf
	1	US-3,830,825	08/20/74	Margraf
\neg	1	US-3,830,908	08/20/74	Klippel et al.
		US-3,856,805	12/24/74	Margraf
		US-3,930,000	12/30/75	Margraf
		US-3,932,627	01/13/76	Margraf
		US-3,954,989	05/04/76	Mecca
		US-4,170,229	10/09/79	Olson
		US-4,278,664	07/14/81	Van Cleave
		US-4,374,766	02/22/83	Puchalski et al.
		US-4,670,263	06/02/87	Noorlander
1		US-4,707,354	11/17/87	Garlen et al.
		US-4,708,813	11/24/87	Snyder
		US-4,806,262	02/21/89	Snyder
		US-4,880,621	11/14/89	Grollier et al.
4		US-4,981,845	01/01/91	Pereira

Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code³-Number⁴-Kind Code³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T^6
7		EPO Publication No. 0242553	10/28/87	Campo	•	
$\overline{}$		EPO Publication No. 0380157	08/01/90	Weisberg		
		PCT Publication No. WO 90/09779	09/07/90	Benhuri		
		Great Britain Patent No. 1,346,544	02/13/74	Margraf		
		Japanese Patent No. JP 358140013A	08/19/83	Kuroda et al. (Dai Ichi Seiyaku et al.) translated		
		Japan Patent Publication No. JP 404208219 English abstract	07/29/92	Abe et al. (abstract only)		
- G		C 1				

Examiner Signature Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. There Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. The following of the standard ST. 16 if possible. Applicant is to place a check mark here if English Insurance Templation is attached. English language Translation is attached.

	Approved for use	tnrougn	10/31/2002.	OWB 0021-003
211	Patent and Trademark Office: 11	S DEP	ARTMENT	OF COMMERCE

Substitute f	or form 1	449B/PTO					Complete if Known	THE		_
		ATION DIS		E icioo	Application	Number	09/939,816	오	ب	而
S	TATEM	ENT BY AF		81_	Filing Date A		August 27, 2001	E CE	5	\Box
			I IIIN 1 1	5005	First Named	Inventor	E. Farber		<u> </u>	口
(use as many sheets as necessary)				₹/	Grou	Art Unit	1614	罗	ورع	
				, et	Exam	ner Name	Not yet assigned		2	9
Sheet	2	of	4 & TRAI	EMA	Attorney Dock	t Number	14358-314	Š	2002	J
								<u> </u>		\Box
				U.S. PAT	FENT DOCU	MENTS		1600/2900)	
Examiner	Cite	Docume	ent Number	Publication	Date		Name of Patentee or			
Examiner nitials*	No. 1	Number -Kind C	Code ² (if known)	MM-DD-YY			Applicant of Cited Document			
	 		05/12/92	Phalang	as					
	<u> </u>	US-5,122,53	3	06/16/92	Bar-On	et al.	<u>, , , , , , , , , , , , , , , , , , , </u>			
	 	US-5,221,53	3	06/22/93	Perlmar	1				
		US-5,455,03	3	10/03/95	Silverm	Silverman et al.				一
	 	US-5,512,20	0	04/30/96	Garcia	Garcia Papakadis				
		US-5,567,42	7	10/22/96	Papakao					
	<u> </u>	US-5,578,31	2	11/26/96	Parrinel	lo				
-4	<u> </u>	US-5,616,34	7	04/01/97	7 Alliger et al.					
				<u> </u>						_
		ОТ	HER PRIOR	ART – NON	PATENT LIT	ERATUR	E DOCUMENTS			
		01	IILICI INTOIC	11011			220001121112			

OTHER PRIOR ART – NONPATENT LITERATURE DOCUMENTS								
Examiner nitials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T^2					
-		Product information insert for Alphosyl Cream and Alphosyl Lotion, G.D. Searle (South Africa), April 24, 1975						
$\overline{}$		Product information insert for Clearasil Medicated Facial Cleanser, Procter & Gamble (South Afrida), Jan. 31, 199						
\		Product information insert for Arola Rosebaum Ointment, Supramed Limited, Jan. 12, 1986						
		Abstract of a publication, M. Cajkovac et al., "Influence of Emulsoid Vehicle on the Release and Activity of Allantoin," Pharmacie 47:39-43 (1992) (abstract only)						
		Abstract of a publication, M. Maragakis et al., "Possibilities of Scar Treatment After Thoracic Surgery," <u>Drugs Under Exp. & Clin. Res.</u> 21:199-206 (1995) (abstract only)						
		Product information insert for Alphosyl, undated.						
		Abstract of a publication, G. Stinco et al., "Seborrheic Dermatitis Treated with Furalglucitole Cream," <u>Dermatol.</u> Clin. 18:78-81 (1998) (abstract only)						
		Abstract of a publication, G.H. Willital & H. Heine, "Efficiency of Contractubex® Gel in the Treatment of Fresh Scars After Thoracic Surgery in Children and Adolescents," Int. J. Clin. Pharmacol. Res. 14:193-202 (1994) (abstract only)						
		H.W. Margraf & T.H. Covey, Jr., "A Trial of Silver-Zinc-Allantoinate in the Treatment of Leg Ulcers," <u>Arch. Surg.</u> 12:699-704 (1977)						
		Remington: The Science and Practice of Pharmacy (19 th Ed. 1995, Mack Publishing Co., Easton, Pennsylvania), pp. 639-640, 1380						
		D. Hoffmann, "The Complete Illustrated Herbal," (Barnes and Noble, 1996), pp. 63, 104						
		F.R. Greenbaum, "The Story of Allantoin," Am. J. Pharm. 112:205-216 (1940)						
		M.A. Lesser, "Allantoin," <u>Drug Cosmet. Ind.</u> 42:451-456, 469 (1938)						

Examiner Date Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached.

			U.S. PATENT	DOCUMENTS
Examiner Cite Initials* No. 1	Cite	Document Number	Publication Date	Name of Patentee or
	Number -Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	
$\overline{}$		US-5,658,559	08/19/97	Smith
	<u> </u>	US-5,661,170	08/26/97	Chodosh
}		US-5,736,128	04/07/98	Chaudhuri et al.
	†	US-5,824,666	10/20/98	Deckner et al.
		US-5,827,870	10/27/98	Chodosh
-	-	US-5,830,483	11/03/98	Seidel et al.
-	 	US-5,863,548	01/26/99	Elder
		US-5,871,754	02/16/99	Briggs et al.
4		US-5,876,736	03/02/99	Cohen et al.

		OTHER PRIOR ART - NONPATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T^2
		I.I. Lubowe & S.B. Mecca, "Allantoin and Aluminum Derivatives in Dermatological Applications,g" <u>Drug Cosmet.</u> <u>Ind.</u> 84:36, 37, 117 (1959)	
	•	S.B. Mecca, "Allantoin and the Newer Aluminum Allantoinates," Proc. Scient. Sect. Toilet Goods Assoc. No. 31: 1-6 (1959)	
		S.B. Mecca, "The Function and Applicability of the Allantoins," <u>Proc. Scient. Sect. Toilet Goods Assoc.</u> No. 39: 7-15 (1963)	
		P. LeVan, "The Use of Silicones in Dermatology," Calif. Med. 81:210-213 (1954)	
		R. Cahen & A. Pessonnier, "Etude Pharmacologique de L'Allantoïnate de Dihydroxyaluminium et de L'Allantoïnate de Chlorhydroxyaluminium. 1 Toxicité," <u>Ann. Pharm. Franç.</u> 20: 623-636 (1962) (in French), discloses the physical and chemical properties and the toxicity of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. The compounds were observed to have no toxicity.	
\		R. Cahen & JF. Clement, "Etude Pharmacologique de L'Allantoïnate de Dihydroxyaluminium et de L'Allantoïnat de Chlorhydroxyaluminium. IIEtude de l'Activité Gastrique," <u>Ann. Pharm. Franç.</u> 20: 693-703 (1962) (in French), discloses the activity of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate on gastri activity. The compounds were found to have acid-neutralizing and buffering activity and to diminish gastric acidity	
		·	_
		•	

	 		<u>" </u>	1			
Examiner	 $\overline{\neg}$	7	<u>"/</u>		Date	 T_{λ}	2
Signature		M	61		Considered	 0)
	 , ,	_				 	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.

Substitute f	or form	14491	B/PTO					Complete if Known	<u></u>	
II	NFORM	MAT.	ION DIS	SCLOURE PLICANT	\$5,190	A	Application Number	09/939,816 — — — — — — — — — — — — — — — — — — —	<u>)</u>	
3	IALL	MEN	IDIA	/	· · · · · · · · · · · · · · · · · · ·		Filing Date	August 27, 2001		
	luca as	man	choote as	necessary)	1002 1002	FII	rst Named Inventor	1614 F m		
	(use us	many	sneets as	(Mecessary)			Group Art Unit		20	
014	-		-£	19			Examiner Name Not yet assigned Attorney Docket Number 14358-314			
Sheet	4		of	4 A TRADE		Atto	mey Docket Number	14358-314	- 2 2	
	-				U.S.	PATENT	DOCUMENTS	14358-314		
Examiner	Cite			ent Number		tion Date		Name of Patentee or		
nitials*	No. 1			Code ² (if known)		D-YYYY		Applicant of Cited Document		
\rightarrow		_ l	S-5,885,58		03/23/9		Massand			
{		1	S-5,914,1		06/22/9		Suares et al.			
T			S-5,932,22		08/03/9		Hall et al.			
		U	S-5,952,3°	73	09/14/9	99	Lanzendörfer et al			
		U:	S-5,958,43	36	09/28/9	9	Hahn et al.	· · · · · · · · · · · · · · · · · · ·		
-+	†	U:	S-6,060,00	51	05/09/0	00	Breton et al.			
	 	U:	S-6,080,39	93	06/27/0	00				
				1		L				
9	1	U:	S-6,120,78	32	09/19/0	00	Mansouri			
>		U:	S-				Mansouri ENT LITERATUR	E DOCUMENTS		
Examiner		_1	O'l	THER PRIOR	ART – Nother (in CA	NONPATI	ENT LITERATUR	rticle (when appropriate), title of the item ge(s), volume-issue number(s), publisher,	T ²	
Examiner		U:	Inclu (book R. Cal L'Alla French	THER PRIOR de name of the au t, magazine, journ then & A. Pessonn antoïnate de Chlor a), discloses the ar ydroxyaluminum	ART – Nother (in CA al, serial, sier, "Etude hydroxyalunti-ulcer ac allantoinat	APITAL LE ymposium, city and/ Pharmacol uminium. I stivity of the te. The con	ENT LITERATUR ETTERS), title of the a catalog, etc.), date, pa or country where publ logique de L'Allantoïn IIEffet Anti-ulcéreu e compounds dihydrox	rticle (when appropriate), title of the item ge(s), volume-issue number(s), publisher, ished ate de Dihydroxyaluminium et de x," Ann. Pharm. Franç. 20: 704-713 (1962) (it yaluminum allantoinate and have anti-ulcer activity in rats and guinea pig	1	
Examiner		U:	R. Cal L'Alla French chlorh compa R. Cal L'Alla Franç. chlorh	ther PRIOR de name of the au then & A. Pessonn intoïnate de Chlor n), discloses the ar ydroxyaluminum intable to compoun then & A. Pessonn intoïnate de Chlor 21: 215-222 (196 ydroxyaluminum ompounds were fo	thor (in CA al, serial, s ier, "Etude hydroxyalu nti-ulcer ac allantoinat ds such as ier, "Etude hydroxyalu ion Fren allantoinat bund to hav	APITAL LE ymposium, city and/ Pharmacoluminium. I tivity of the ce. The con aluminum is Pharmacoluminium. I ach), discloste on ulcers re activity a	ENT LITERATUR ETTERS), title of the a catalog, etc.), date, pa for country where publ logique de L'Allantoïn II.—Effet Anti-ulcéreu e compounds dihydrox apounds were found to hydrate and bismuch s logique de L'Allantoïn V.—Effet sur l'Ulcère ses the effect of the corproduced in the rat by gainst such ulcers.	rticle (when appropriate), title of the item ge(s), volume-issue number(s), publisher, ished ate de Dihydroxyaluminium et de x," Ann. Pharm. Franç. 20: 704-713 (1962) (in yaluminum allantoinate and have anti-ulcer activity in rats and guinea pigubnitrate. ate de Dihydroxyaluminium et de Médicamenteux Expérimental," Ann. Pharm. mpounds dihydroxyaluminum allantoinate and administration of phenylbutazone or reserping	S S	
Examiner		U:	Inclu (book R. Cal L'Alla French chlorh compa R. Cal L'Alla French chlorh compa Chlorh The cc C. De duodé dihydr of poly	de name of the au and a managazine, journ and a A. Pessonn antoïnate de Chlor and a compount a A. Pessonn antoïnate de Chlor and a A. Pessonn antoïnate de Chlor a 1: 215-222 (196 and a managazine a A. Pessonn antoïnate de Chlor a 1: 215-222 (196 and a Managazine a A. "Etude and a compound a were for a compound a managazine a A. "Etude and a compound a la la compound a la compou	thor (in CA al, serial, sier, "Etude hydroxyaluti-ulcer ac allantoinat ds such as ier, "Etude hydroxyalution for allantoin for allantoin to have de Dèrivé d. 70: 2643 antoinate an polyoxypro	APITAL LE ymposium, city and/ Pharmacol uminium. I stivity of the re. The con aluminium. I inch), discloste on ulscesse activity a s Allantoïn 3-2644 (196 nd chlorby opanediol,	ENT LITERATUR ETTERS), title of the a catalog, etc.), date, pa or country where publ logique de L'Allantoïn IIEffet Anti-ulcéreu e compounds dihydrox mpounds were found to hydrate and bismuch s logique de L'Allantoïn VEffet sur l'Ulcère ses the effect of the corproduction of t	rticle (when appropriate), title of the item ge(s), volume-issue number(s), publisher, ished ate de Dihydroxyaluminium et de x," Ann. Pharm. Franç. 20: 704-713 (1962) (ii yaluminum allantoinate and have anti-ulcer activity in rats and guinea pig ubnitrate. ate de Dihydroxyaluminium et de Médicamenteux Expérimental," Ann. Pharm. mpounds dihydroxyaluminum allantoinate and	s s	
Examiner		U:	Inclu (book R. Cal L'Alla French chlorh compa R. Cal L'Alla French chlorh Compa Chlorh The cc C. De duodé dihydr of poly condit	de name of the au and a managazine, journ and a A. Pessonn antoïnate de Chlor and a compount a A. Pessonn antoïnate de Chlor and a A. Pessonn antoïnate de Chlor a 1: 215-222 (196 and a managazine a A. Pessonn antoïnate de Chlor a 1: 215-222 (196 and a Managazine a A. "Etude and a compound a were for a compound a managazine a A. "Etude and a compound a la la compound a la compou	thor (in CA al, serial, sier, "Etude hydroxyaluti-ulcer ac allantoinat ds such as ier, "Etude hydroxyalution for allantoin for allantoin to have de Dèrivé d. 70: 2643 antoinate an polyoxypro	APITAL LE ymposium, city and/ Pharmacol uminium. I stivity of the re. The con aluminium. I inch), discloste on ulscesse activity a s Allantoïn 3-2644 (196 nd chlorby opanediol,	ENT LITERATUR ETTERS), title of the a catalog, etc.), date, pa or country where publ logique de L'Allantoïn IIEffet Anti-ulcéreu e compounds dihydrox mpounds were found to hydrate and bismuch s logique de L'Allantoïn VEffet sur l'Ulcère ses the effect of the corproduction of t	rticle (when appropriate), title of the item ge(s), volume-issue number(s), publisher, ished ate de Dihydroxyaluminium et de x," Ann. Pharm. Franç. 20: 704-713 (1962) (it yaluminum allantoinate and have anti-ulcer activity in rats and guinea pigubnitrate. ate de Dihydroxyaluminium et de Médicamenteux Expérimental," Ann. Pharm. mpounds dihydroxyaluminum allantoinate and administration of phenylbutazone or reserpindans la Thérapeutique des Affections Gastroses the activity of the compounds binate administered in a complex with a polymomide, and calcium carbonate on gastrointestic	s s	
Examiner Initials		U:	Inclu (book R. Cal L'Alla French chlorh compa R. Cal L'Alla French chlorh Compa Chlorh The cc C. De duodé dihydr of poly condit	de name of the au and a managazine, journ and a A. Pessonn antoïnate de Chlor and a compount a A. Pessonn antoïnate de Chlor and a A. Pessonn antoïnate de Chlor a 1: 215-222 (196 and a managazine a A. Pessonn antoïnate de Chlor a 1: 215-222 (196 and a Managazine a A. "Etude and a compound a were for a compound a managazine a A. "Etude and a compound a la la compound a la compou	thor (in CA al, serial, sier, "Etude hydroxyaluti-ulcer ac allantoinat ds such as ier, "Etude hydroxyalution for allantoin for allantoin to have de Dèrivé d. 70: 2643 antoinate an polyoxypro	APITAL LE ymposium, city and/ Pharmacol uminium. I stivity of the re. The con aluminium. I inch), discloste on ulscesse activity a s Allantoïn 3-2644 (196 nd chlorby opanediol,	ENT LITERATUR ETTERS), title of the a catalog, etc.), date, pa or country where publ logique de L'Allantoïn IIEffet Anti-ulcéreu e compounds dihydrox mpounds were found to hydrate and bismuch s logique de L'Allantoïn VEffet sur l'Ulcère ses the effect of the corproduction of t	rticle (when appropriate), title of the item ge(s), volume-issue number(s), publisher, ished ate de Dihydroxyaluminium et de x," Ann. Pharm. Franç. 20: 704-713 (1962) (it yaluminum allantoinate and have anti-ulcer activity in rats and guinea pigubnitrate. ate de Dihydroxyaluminium et de Médicamenteux Expérimental," Ann. Pharm. mpounds dihydroxyaluminum allantoinate and administration of phenylbutazone or reserpindans la Thérapeutique des Affections Gastroses the activity of the compounds binate administered in a complex with a polymomide, and calcium carbonate on gastrointestic	s s	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached.

Considered

Signature



PTO/SB/08A (10-01)

Approved for use through 10/377902. OMB 0651-0031 ademark Office: U.S. DEPARIAMENT OF COMMELCE

					ent and Trademark Office. U.S.	DEI MEREN	01 00	MINIT
Substitut	e for form 1449	A/PTO	TRADEN		Complete if Known	7	ال	m
	INFORMAT	ION DI	SCLOSURE	Application Number	09/939,816	ENTE	UN 1	CE
	STATEMEN	NT BY A	PPLICANT	· Filing Date	August 27, 2001	3	မ]
				First Named Inventor	E. Farber	5	2	
	(use as man	y sheets a	s necessary)	· Art Unit	1614	8	00	lmi
				Examiner Name	Not assigned	/28	7	
Sheet	5	of	5	Attorney Docket Number	14358-314	8		

		<u>.</u>	U.S. PATENT	DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	
Initials*	No. 1	Number -Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	
*	1	US-4,478,853	10/23/84	Chaussee	
		US-4,507,279	03/26/85	Okuyama et al.	
\neg		US-5,709,847	01/20/98	Bissett et al.	
- 1	1	US-5,849,310	12/15/98	Trinh et al.	
	1	US-5,968,528	10/19/99	Deckner et al.	
		US-6,001,377	12/14/99	SaNogueira, Jr. et al.	
\neg		US-6,086,903	07/11/00	Trinh et al.	
1		US-6,174,533 B1	01/16/01	SaNogueira, Jr. et al.	
7	 	US-6,306,915 B1	10/23/01	Murata	
		US-6,337,065 B1	01/08/02	Jacobson et al.	

-		FORE	IGN PATENT DO	DCUMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code³-Number⁴-Kind Code³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T _e

OTHER PRIOR ART – NONPATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	

	ĵ.		
Examiner Signature	5/1	Date Considered	5/03

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

^{*}EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The Tentral Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is

^{*}Substitute Disclosure Statement Form (PTO-1449)